Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
(Reuters) - Biotech startup Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN) Plc and Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offering.
The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raised $216 million to date from Gilead Sciences (NASDAQ:GILD), Sequoia Capital China and Oxford Sciences Innovation among others.
The UK-based company, spun out of Jenner Institute at the Oxford University in 2016, said it plans to list its American Depositary Shares (ADS) on Nasdaq under the ticker symbol "VACC".
I think Lindy is worth every penny of that wage.
Biontech`s Sahin received a cool reception in the stock market, which initially valued BioNTech at $3.4 billion. With the development of the vaccine, however, BioNTech’s stock has risen by 900% since its 2019 IPO and today the company is valued at $37 billion.
https://www.forbes.com/sites/nathanvardi/2021/04/19/the-billionaire-scientist-behind-the-pfizer-vaccine-has-not-sold-a-single-share-of-his-booming-stock/#:~:text=EDT%20%7C357%2C082%20views-,The%20Billionaire%20Scientist%20Behind%20The%20Pfizer%2DBioNTech%20Vaccine%20Has%20Not,Share%20Of%20His%20Booming%20Stock&text=U%C4%9Fur%20%C5%9Eahin%2C%20founder%20of%20the%20Mainz%20corona%20vaccine%20developer%20BioNTech.
Yes exactly. Exciting Ray.
https://youtu.be/VEbic53pJ_A?t=1351
https://www.bloomberg.com/news/articles/2021-01-11/sanofi-to-buy-antibody-maker-kymab-in-1-45-billion-deal?cmpid=socialflow-twitter-business&utm_source=twitter&utm_medium=social&utm_content=business&utm_campaign=socialflow-organic
Peptron signs global rights for ADC candidate over to Qilu
April 21, 2021
By Gina Lee and Elise Mak
HONG KONG – Qilu Pharmaceutical Ltd. has inked a deal for the global rights to Peptron Inc.’s antibody-drug conjugate (ADC) candidate PAb-001-ADC for the treatment of various cancers. Seoul, South Korea-based Peptron stands to receive an up-front payment of $3 million and $539 million in milestone payments, as well as royalties.
Summary
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142–144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.)
https://www.nejm.org/doi/full/10.1056/NEJMoa2105000#.YICXOcsmN34.twitter
Professor Durrant is also part of our dedicated and valued Continuum Nottingham University team, researching our unique Continuum cohort of long term cancer survivors. We are expecting to announce exciting developments soon!
So proud of you all.
https://www.continuumlifesciences.com/lindy-durrant-and-her-team-developing-mutation-resistant-covid-19-vaccine/
https://www.bloomberg.com/news/articles/2021-04-18/oxford-starts-first-study-to-reinfect-recovered-covid-patients
Challenge trials, involving deliberate, supervised infections, are seen as particularly helpful for answering questions like these, because they allow scientists to scrutinize the details of how the body confronts the virus and vice versa.
https://www.reuters.com/article/us-health-coronavirus-israel-study-idUSKBN2BX0JZ
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.
The Nigerian variant has a higher case fatality rate, at 4.3 per cent, than the South African strain at 2.2 per cent and the Kent variant at 2.3 per cent, according to documents seen by i. B1351 has so far accounted for nine UK deaths while 12 people have died with the B1525 variant.
https://inews.co.uk/news/health/concerns-grow-over-covid-19-variants-following-a-sharp-increase-in-cases-946525
When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues analyzed blood cell samples from 30 people who had contracted and recovered from COVID-19 prior to the emergence of virus variants. They found that one key player in the immune response to SARS-CoV-2—the CD8+ T cell—remained active against the virus.
In their study of recovered COVID-19 patients, the researchers determined that SARS-CoV-2-specific CD8+ T-cell responses remained largely intact and could recognize virtually all mutations in the variants studied. While larger studies are needed, the researchers note that their findings suggest that the T cell response in convalescent individuals, and most likely in vaccinees, are largely not affected by the mutations found in these three variants, and should offer protection against emerging variants.
HTTPS://www.nih.gov/news-events/news-releases/t-cells-recognize-recent-sars-cov-2-variants#.YGRq0xBxpv4.twitter
Yes correct, many AIM if held for 2yrs however there is Bob Hope chance that Scancell will not be taken over if successful.
Maybe a fund of qualifying AIM shares towards the end of our lives is the answer?
Any government can change the rules of course. That would be my luck!
One thing to understand;
ISAs are not free from inheritance tax (IHT). If they are given on your death to your surviving spouse or civil partner they will not be subject to IHT because of the spouse exemption.
What happens to an ISA when the owner dies?
Once the owner dies, the ISA treatment ceases, and it becomes a part of the estate like any other investment. The deceased's personal representatives (PR) will be responsible for the inheritance tax on the ISA, and also tax on any gains or income which arise on the estate from then on.
armed oncolytic viruses and T-cell therapy
https://www.prnewswire.co.uk/news-releases/tilt-biotherapeutics-advances-cancer-immunotherapy-clinical-trial-achieving-primary-end-point-in-the-first-cohort-802777716.html
Search for 'universal' coronavirus vaccine heats up with major cash injection
There have been three major new coronavirus threats in recent years - developing a broadly protective vaccine is urgent, say scientists
More broadly protective vaccines could guard against Covid-19 variants and even other coronaviruses - but there is a lot of work to be done CREDIT: AFP
The hunt for a vaccine that protects against all Covid-19 variants as well as other coronaviruses is set to heat up with “nine-figure” funding injection, The Telegraph can reveal.
Around 20 teams around the world are at the early stages of developing vaccines that offer broader protection against a range of coronaviruses, from Covid-19 to Sars. So-called universal vaccines of this type have long been a holy grail in the fight against infectious diseases, such as flu, and could be important not just for this pandemic but for heading off future threats.
Now the Coalition for Epidemic Preparedness Innovations (Cepi), a key player in the development of Covid-19 vaccines, is set to announce a “call for proposals” for researchers working on universal coronavirus vaccines, with hundreds of millions of dollars of funding available.
Dr Richard Hatchett, chief executive of Cepi, told The Telegraph: “This is the third coronavirus in the 21st century, and that ought to be the hair-on-fire urgency to take coronavirus off the table.
“So in the next couple of weeks we’ll be announcing a very significant investment in developing broadly protecting or even universal coronavirus vaccine.”
However, he stressed that there was a lot of work to be done before any vaccines of this type are likely to be available. For example, scientists have been trying to develop a universal flu vaccine for decades, without success.
One of the key sticking points is making sure that any vaccine against different viruses from the same family generates a strong enough immune response to each in order to protect against infection.
However, Dr Hatchett said the progress made so far in developing vaccines for Covid-19 was an “encouraging” sign.
A number of teams, including the cancer company Scancell and scientists from the University of Nottingham, have showed promising early results in animal testing of their vaccine candidates, which have the potential to offer broader protection because of how they are designed.
“The question is, can we find that Achilles heel across the whole family that would be something that we could target, that is conserved, and important, in a way that we could leverage,” said Dr Hatchett.
“There is a lot of work to be done.”
As well as antibodies, the body’s T-cell response is also increasingly thought to be important and targetable for coronavirus vaccines.
Other vaccine candidates in development target different parts of the immune system depending on how they are administered: for example, nasal spray vaccines.
Cepi to outline its priorities for the next five years, on w
SCANCELL Retweeted
Wellcome
@wellcometrust
·
5h
As more #Covid19 variants emerge, it increases the risk that a variant emerges that our current tools aren't effective against.
That's why we need to keep investing in a variety of vaccines and treatments
https://twitter.com/wellcometrust/status/1368251783735373828?s=20
Yes it is cleanerworld. I hope that Scancell do not sell or license too cheaply.
anti-FGFR2b antibody
$MRK offered $PAND 65min in Jan, 2020 and $PAND said F that, IPO'd, turned down 100mil partnership in Oct, 2020 and then $MRK ended up paying 1.85bil in Mar, 2021
Amgen is paying $38 a share, putting the deal value at $1.9 billion. 78% premium.
The drug certainly still has much to prove, and safety concerns to overcome. But the data, as complex as they were, still saw its shares jump omn the readout in November last year by 300%, and made it an attractive buyout option for a big company, which has turned out to be Amgen. It nabs the biotech for $38 per share in cash, or around $1.9 billion, a major 78% premium over its $21 close yesterday.
This is also a major leap from the around $5 a share it was trading at before the bemarituzumab data came out.
https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal
anti-FGFR2b antibody
Five Prime's lead asset, bemarituzumab, is a first-in-class, anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
https://www.prnewswire.com/news-releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-301240358.html